Summary of Study ST002850

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR001784. The data can be accessed directly via it's Project DOI: 10.21228/M83T50 This work is supported by NIH grant, U2C- DK119886.


This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002850
Study TitleBap1 Promotes Osteoclast Function by Metabolic Reprogramming
Study TypeUntargeted Metabolomics
Study SummaryTreatment of osteoporosis most commonly diminishes osteoclast number which suppresses bone formation thus compromising fracture prevention. Bone formation is not suppressed, however, when bone degradation is reduced by retarding osteoclast functional resorptive capacity, rather than differentiation. We find deletion of deubiquitinase, BRCA1-associated protein 1 (Bap1), in myeloid cells (Bap1∆LysM), arrests osteoclast function but not formation. Bap1∆LysM osteoclasts fail to organize their cytoskeleton which is essential for bone degradation. Consequently, bone mass increases in the mutant mice. We find the deubiquitinase activity of Bap1 regulates osteoclast function by metabolic reprogramming. Bap1 deficient osteoclast lineage cells upregulate the cystine transporter, Slc7a11, by enhanced H2Aub occupancy of its promoter. SLC7A11 regulates cellular ROS levels and redirects the mitochondrial metabolites away from the TCA cycle, both of which are necessary for osteoclast function. Thus in osteoclasts, Bap1 appears to regulate epigenetic-metabolic axis and is a potential target to reduce bone degradation while maintaining osteogenesis in osteoporotic patients.
Washington University in St. Louis
DepartmentPathology and Immunology, Medicine, Chemistry
LaboratoryTeitelbaum and Patti Laboratories
Last NameCho
First NameKevin
Address1 Brookings Drive, Campus Box 1134, St. Louis, MO, 63130, USA
Submit Date2023-08-26
Raw Data AvailableYes
Raw Data File Type(s)mzML
Analysis Type DetailLC-MS
Release Date2023-09-11
Release Version1
Kevin Cho Kevin Cho application/zip

Select appropriate tab below to view additional metadata details:

Combined analysis:

Analysis ID AN004668 AN004669
Analysis type MS MS
Chromatography type HILIC HILIC
Chromatography system Thermo Vanquish Flex UHPLC Systems Thermo Vanquish Flex UHPLC Systems
Column HILICON iHILIC-(P) Classic (100 x 2.1mm,5um) HILICON iHILIC-(P) Classic (100 x 2.1mm,5um)
MS instrument type Orbitrap Orbitrap
MS instrument name Thermo Orbitrap ID-X tribrid Thermo Orbitrap ID-X tribrid
Units peak area peak area


Chromatography ID:CH003514
Instrument Name:Thermo Vanquish Flex UHPLC Systems
Column Name:HILICON iHILIC-(P) Classic (100 x 2.1mm,5um)
Column Temperature:45
Flow Gradient:0–1 min: 90% B, 1–12 min: 90-35% B, 12–12.5 min: 35-25% B, 12.5–14.5 min: 25% B
Flow Rate:250 uL/min
Solvent A:20 mM ammonium bicarbonate, 0.1% ammonium hydroxideand 2.5 μM medronic acid in water:acetonitrile (95:5)
Solvent B:acetonitrile:water (95:5)
Chromatography Type:HILIC